(Total Views: 529)
Posted On: 04/13/2020 8:14:59 PM
Post# of 153880
~66% of volume today was sold short. Just building up for a rocket blast off on FDA approval news.
Good thing for CYDY is that patients show vast improvement quickly. Half the trial population will probably be sent hone before everyone is enrolled. If it turns out that a high percentage of those being sent home are from the 2/3 actually receiving lero, then there's a chance the FDA moves ahead and approves lero and wait to analyze the data afterward, especially if the doctors administering the trials believe that their patient's are improving because of lero (because it's so obvious) and begin voicing their concerns over the days of their patients due to FDA bureaucracy.
Might be we get excellent news by next Monday.
Good thing for CYDY is that patients show vast improvement quickly. Half the trial population will probably be sent hone before everyone is enrolled. If it turns out that a high percentage of those being sent home are from the 2/3 actually receiving lero, then there's a chance the FDA moves ahead and approves lero and wait to analyze the data afterward, especially if the doctors administering the trials believe that their patient's are improving because of lero (because it's so obvious) and begin voicing their concerns over the days of their patients due to FDA bureaucracy.
Might be we get excellent news by next Monday.
(1)
(0)
